Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
U-Neuron BiomedicalROCO:6973 +0.91%12 PS Ratio is 15.55 as of Jul. 19, 2026, which is 47% below its 10-year median of 29.07. GuruFocus rates ROCO:6973 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 931 Biotechnology companies, U-Neuron Biomedical ranks worse than 61.44% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, U-Neuron Biomedical's share price is NT$33.10.
U-Neuron Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2.13. Hence, U-Neuron Biomedical's PS Ratio for today is 15.55.
Good Sign:
U-Neuron Biomedical Inc stock PS Ratio (=15.56) is close to 3-year low of 15.04.
The historical rank and industry rank for U-Neuron Biomedical's PS Ratio or its related term are showing as below:
ROCO:6973'
s PS Ratio Range Over the Past 10 Years
Min: 15.04 Med: 29.07 Max: 48.84
Current: 15.55
During the past 6 years, U-Neuron Biomedical's highest PS Ratio was 48.84. The lowest was 15.04. And the median was 29.07.
ROCO:6973's PS Ratio is ranked worse than 61.44% of 931
companies
in the Biotechnology industry
Industry Median: 9.32
vs ROCO:6973: 15.55
During the past 6 years, U-Neuron Biomedical's highest 3-Year average Revenue per Share Growth Rate was 8.30% per year. The lowest was -16.60% per year. And the median was -4.15% per year.
Back to Basics: PS Ratio
U-Neuron Biomedical (ROCO:6973) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
U-Neuron Biomedical PS Ratio Related Terms
U-Neuron Biomedical PS Ratio Historical Data
* Premium members only.
The historical data trend for U-Neuron Biomedical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6973 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, U-Neuron Biomedical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
U-Neuron Biomedical PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's PS Ratio distribution charts can be found below:
* The bar in red indicates where U-Neuron Biomedical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
U-Neuron Biomedical's Share Price of today is NT$33.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. U-Neuron Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2.13.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
U-Neuron Biomedical (ROCO:6973) has a PS Ratio of 15.55 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on U-Neuron Biomedical and its competitors. This is 47% below median its historical median of 29.07. Over the past decade, U-Neuron Biomedical's PS Ratio has ranged from 15.04 to 48.84. According to the industry distribution chart, U-Neuron Biomedical ranks #572 out of 931 companies in the Biotechnology industry, placing it in the top 61.4%.
Is U-Neuron Biomedical's PS Ratio too high?
U-Neuron Biomedical's current PS Ratio of 15.55 is 47% below median its 10-year median of 29.07. Over the past 10 years, this metric has ranged from a low of 15.04 to a high of 48.84. The Biotechnology industry median PS Ratio is 9.32. U-Neuron Biomedical's value of 15.55 is 66.8% above this industry median. Based on the distribution chart, U-Neuron Biomedical ranks #572 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, U-Neuron Biomedical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, U-Neuron Biomedical ranks #572 out of 931 companies for PS Ratio. This places U-Neuron Biomedical in the lower half of its industry. The industry median PS Ratio is 9.32. U-Neuron Biomedical's value of 15.55 is 66.8% above this benchmark. Historically, U-Neuron Biomedical's own PS Ratio has ranged from 15.04 to 48.84 over the past decade. While the company's 10-year median is 29.07 vs. the industry median of 9.32, U-Neuron Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.32, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. U-Neuron Biomedical's current PS Ratio of 15.55 is 66.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on U-Neuron Biomedical and its competitors. For the Biotechnology industry, the median PS Ratio is 9.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. U-Neuron Biomedical's current PS Ratio is 15.55, which is 47% below median its own 10-year median of 29.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
U-Neuron Biomedical (ROCO:6973) has a current PS Ratio of 15.55. The current PS Ratio is 15.55, which is 47% below median its 10-year median of 29.07 and 66.8% above the Biotechnology industry median of 9.32. U-Neuron Biomedical's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current PS Ratio is 15.55 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
12GF Score
Get the complete analysis for ROCO:6973
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6973 has been successfully added to your 
